Drugs / MK-5160
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03095651 | Apr 2017 → Jan 2018 | type 1 diabetes mellitus, type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-5160 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03095651 ↗ |
| Route | Subcutaneous | “subcutaneous injection administered daily” NCT03095651 ↗ |